Teleflex Stock (NYSE:TFX)
Previous Close
$235.22
52W Range
$190.49 - $257.85
50D Avg
$240.80
200D Avg
$226.91
Market Cap
$9.47B
Avg Vol (3M)
$347.70K
Beta
1.16
Div Yield
$1.36 (0.68%)
TFX Company Profile
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site. The company also offers interventional products, which consists of various coronary catheters, structural heart therapies, and peripheral intervention and cardiac assist products that are used by interventional cardiologists and radiologists, and vascular surgeons; and Arrow branded catheters, Guideline and Trapliner catheters, the Manta Vascular Closure, and Arrow Oncontrol devices. It provides anesthesia products, such as airway and pain management products to support hospital, emergency medicine, and military channels; and surgical products, including metal and polymer ligation clips, and fascial closure surgical systems that are used in laparoscopic surgical procedures, percutaneous surgical systems, and other surgical instruments. The company also offers interventional urology products comprising the UroLift System, an invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia; and respiratory products, including oxygen and aerosol therapies, spirometry, and ventilation management products for use in various care settings. It provides urology products, such as catheters, urine collectors, and catheterization accessories and products for operative endourology; and bladder management services. The company serves hospitals and healthcare providers, medical device manufacturers, and home care markets. The company was incorporated in 1943 and is headquartered in Wayne, Pennsylvania.
TFX Performance
Revenue Breakdown
Revenue Breakdown by Product/Service
Product/Service | Dec 23 | Dec 22 | Dec 21 |
---|---|---|---|
Anesthesia | $389.96M | $388.89M | $380.14M |
Surgical | $427.36M | $392.92M | $377.76M |
Vascular Access | $708.04M | $683.61M | $700.24M |
Other | $291.90M | $285.15M | $336.58M |
Interventional | $511.43M | $445.02M | $427.50M |
Interventional Urology | $319.79M | $322.83M | $341.66M |
Oem | - | $272.62M | $245.68M |
Peer Comparison
Ticker | Company |
---|---|
MMSI | Merit Medical Systems, Inc. |
COO | The Cooper Companies, Inc. |
WST | West Pharmaceutical Services, Inc. |
BDX | Becton, Dickinson and Company |
HOLX | Hologic, Inc. |
ALC | Alcon Inc. |
RMD | ResMed Inc. |
NVST | Envista Holdings Corporation |
ANGO | AngioDynamics, Inc. |
HAE | Haemonetics Corporation |
ICUI | ICU Medical, Inc. |
ATR | AptarGroup, Inc. |